Secretory and proliferative activities of the prostate gland are strictly dependent on androgenic hormones. However, little is known about the mechanism(s) of androgenic regulated gene expression at the molecular level. The proposed studies will focus on the prostate-specific kallikrein genes, (prostate-specific antigen, PSA and human glandular kallikrein, hGK- 1) to study androgen mediated gene regulation in the androgen responsive prostatic cell line, LNCaP, as a model system. Preliminary experiments have shown that LNCaP cells respond to androgens by increased production of both PSA and hGK-1. Sequence analysis of cloned 5' flanking regions of the kallikrein genes revealed a putative steroid response element (SRE). Therefore, PSA and hGK-1 specific DNA probes will be used to determine whether androgens act at the transcriptional and/or post-transcriptional level. Several complementary approaches will be used to characterize this putative SRE sequence and to identify other cis regulatory elements (i.e., prostate-specific elements) which are important for control of kallikrein gene expression. These will include: 1) gene transfer experiments, 2) in vitro DNA-protein interaction assays (e.g., DNase 1 foot printing, band shifting, methylation interference, etc.), and 3) mutational analysis. Achievement of these objectives should provide valuable insight into the androgenic and tissue-specific regulation of the prostatic kallikrein genes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK041995-01A2
Application #
3242971
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1991-09-01
Project End
1994-08-31
Budget Start
1991-09-01
Budget End
1992-08-31
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Spitzweg, C; Scholz, I V; Bergert, E R et al. (2003) Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology 144:3423-32
Chung, B H; Mitchell, S H; Zhang, J S et al. (2001) Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 22:1201-6
Xing, N; Chen, Y; Mitchell, S H et al. (2001) Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22:409-14
Xing, N; Qian, J; Bostwick, D et al. (2001) Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48:7-15
Zhu, W; Zhang, J S; Young, C Y (2001) Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22:1399-403
Zhu, W; Young, C Y (2001) Androgen-Dependent transcriptional regulation of the prostate-specific antigen gene by thyroid hormone 3,5,3'-L-triiodothyronine. J Androl 22:136-41
Spitzweg, C; Dietz, A B; O'Connor, M K et al. (2001) In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8:1524-31
Mitchell, S H; Murtha, P E; Zhang, S et al. (2000) An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol 168:89-99
Spitzweg, C; O'Connor, M K; Bergert, E R et al. (2000) Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60:6526-30
Butler, R; Mitchell, S H; Tindall, D J et al. (2000) Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 11:49-61

Showing the most recent 10 out of 28 publications